BeOne Medicines (NASDAQ:ONC) COO Sells $163,511.20 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 626 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $261.20, for a total value of $163,511.20. Following the completion of the transaction, the chief operating officer owned 1,308,161 shares in the company, valued at approximately $341,691,653.20. This trade represents a 0.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaobin Wu also recently made the following trade(s):

• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The stock was sold at an average price of $269.37, for a total value of $399,745.08.

BeOne Medicines Trading Down 0.5%

NASDAQ:ONC opened at $262.68 on Thursday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22. The business’s 50-day simple moving average is $296.83 and its 200 day simple moving average is $312.94. The stock has a market cap of $28.82 billion, a price-to-earnings ratio of 58.77 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion for the quarter. As a group, sell-side analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ONC has been the topic of several research reports. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Wolfe Research initiated coverage on BeOne Medicines in a research note on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective on the stock. Royal Bank Of Canada upped their price objective on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Wells Fargo & Company initiated coverage on BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective on the stock. Finally, Zacks Research upgraded BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, June 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors have recently made changes to their positions in the stock. Mariner LLC grew its holdings in shares of BeOne Medicines by 3.8% during the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after purchasing an additional 32 shares during the last quarter. Signaturefd LLC grew its holdings in shares of BeOne Medicines by 10.7% during the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock valued at $103,000 after purchasing an additional 33 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after purchasing an additional 39 shares during the last quarter. CWM LLC grew its holdings in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the last quarter. Finally, Benjamin Edwards Inc. grew its holdings in shares of BeOne Medicines by 8.0% during the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after purchasing an additional 51 shares during the last quarter. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.